Literature DB >> 27799400

Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.

Robert S Wallis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27799400     DOI： 10.1183/13993003.01207-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  14 in total

Review 1.  Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.

Authors:  Estefania Grotz; Nancy Tateosian; Nicolas Amiano; Maximiliano Cagel; Ezequiel Bernabeu; Diego A Chiappetta; Marcela A Moretton
Journal:  Pharm Res       Date:  2018-09-20       Impact factor: 4.200

Review 2.  Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

Authors:  Lia D'Ambrosio; Rosella Centis; Simon Tiberi; Marina Tadolini; Margareth Dalcolmo; Adrian Rendon; Susanna Esposito; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

3.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

4.  Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.

Authors:  Fangchao Liu; Jingtao Gao; Mengqiu Gao; Yuhong Liu; Wei Shu; Li Xie; Yuxian Sun; Lijie Zhang; Liang Li; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2022-09-01       Impact factor: 5.938

5.  Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.

Authors:  Mahmoud Tareq Abdelwahab; Richard Court; Daniel Everitt; Andreas H Diacon; Rodney Dawson; Elin M Svensson; Gary Maartens; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

6.  Submission for Special Issue: The Role of Platelet Activation in the Pathophysiology of HIV, Tuberculosis, and Pneumococcal Disease. Bedaquiline Suppresses ADP-Mediated Activation of Human Platelets In Vitro via Interference With Phosphatidylinositol 3-Kinase.

Authors:  Gregory R Tintinger; Annette J Theron; Helen C Steel; Moloko C Cholo; Jan G Nel; Charles Feldman; Ronald Anderson
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 7.  Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Authors:  Giovanni Battista Migliori; Emanuele Pontali; Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Simon Tiberi; Marina Tadolini; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2017-02-07       Impact factor: 5.923

8.  Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Authors:  Andrey Maryandyshev; Emanuele Pontali; Simon Tiberi; Onno Akkerman; Shashank Ganatra; Tsetan Dorji Sadutshang; Jan-Willem Alffenaar; Rohit Amale; Jai Mullerpattan; Sonam Topgyal; Zarir Farokh Udwadia; Rosella Centis; Lia D'Ambrosio; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  Emerg Infect Dis       Date:  2017-10-17       Impact factor: 6.883

9.  Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro.

Authors:  Ronald Anderson; Annette J Theron; Jan G Nel; Chrisna Durandt; Moloko C Cholo; Charles Feldman; Gregory R Tintinger
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

10.  Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.

Authors:  Levin Thomas; Sumit Raosaheb Birangal; Rajdeep Ray; Sonal Sekhar Miraj; Murali Munisamy; Muralidhar Varma; Chidananda Sanju S V; Mithu Banerjee; Gautham G Shenoy; Mahadev Rao
Journal:  Ther Adv Drug Saf       Date:  2021-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.